A phase 2 clinical trial of ORP-101
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs ORP 101 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 30 Apr 2018 New trial record
- 25 Apr 2018 According to an OrphoMed media release, in May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. This capital will be used to advance the clinical development of ORP-101 through Phase 2.
- 25 Apr 2018 According to an OrphoMed media release, the goal of the company is to advance ORP-101 into Phase 2 by the end of 2018.